Featured Jobs
|
Daybright Financial
|
|
Nova 401(k) Associates
|
|
Independent Retirement
|
|
Regional Sales Director-Mid Atlantic July Business Services
|
|
Director, Strategic Accounts and Channel Development July Business Services
|
|
Director of Regulatory Operations and Compliance PCS Retirement
|
|
EPIC RPS
|
|
Regional Sales Director-Heartland July Business Services
|
|
Internal Channel Sales Team Lead July Business Services
|
|
EPIC RPS
|
|
Experienced Employee Benefits Attorney Shipman & Goodwin LLP
|
|
Relationship Manager – Defined Contributions Daybright Financial
|
|
Spectrum Pension Consultants (part of Daybright Financial)
|
|
Stones River Consulting
|
|
Daybright Financial
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
GLP-1 Drugs for Weight Loss: The Good, Bad and Unknown
Benefitfocus 
Sept. 5, 2025 "While covering these drugs may serve employees' needs and potentially increase satisfaction with their employee benefits package ... many employers hesitate to offer new coverage from a cost perspective alone. A 2025 article ... reports a notable increase in the average representation of GLP-1 drugs used for weight loss in total annual claims for employers, increasing from 8.9 percent in 2024 to 10.5 percent in 2025. Overall, 36 percent of employers are providing GLP-1 coverage for both diabetes and weight loss (up from 34 percent in 2024)." MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |